Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Copyright 2024 – Finance News Network
Source: Finance News Network
27 Jun 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.
Read More11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
Read More18 Dec 2019 - Oventus Medical Limited (ASX:OVN) Managing Director and CEO, Dr Chris Hart talks about the company's North American sales process via its lab in lab model and how this improves patient outcomes.
Read More16 Oct 2024 - Rita Gatt, National Lead Partner - Regulation, Security and Risk at Deloitte, discusses the revolutionary potential of quantum computing.
Read More05 May 2022 - Elementos Limited (ASX:ELT) Managing Director Joe David discusses factors behind the recent increase in the tin price and outlines Elementos' key project in Oropesa, Spain.
Read More24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.
Read More10 Oct 2023 - Harry Fisher - Project Manager - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Read More16 Sep 2019 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams discusses the company’s high-grade exploration results from its northern NSW project, plus how it’s poised to benefit from the rise of ‘critical minerals’ designation.
Read More11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
Read More21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
Read More
